Biogen is urging CMS to reconsider a proposed guidance that would significantly limit coverage of its Alzheimer’s drug Aduhelm.
Read the full post on Becker's Hospital Review - Healthcare News
Biogen to CMS: Reverse Aduhelm’s proposed coverage limits
